Cargando…

Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan

Busulfan has been used as a conditioning regimen in allogeneic hematopoietic cell stem transplantation (HSCT). Owing to a large inter-individual variation in pharmacokinetics, therapeutic drug monitoring (TDM)-guided busulfan dosing is necessary to reduce graft failure and relapse rate. As there exi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Rong-Long, Fang, Li-Hua, Yang, Xin-Yi, El Amrani, Mohsin, Uijtendaal, Esther Veronique, Chen, Yen-Fu, Ku, Wei-Chi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308703/ https://www.ncbi.nlm.nih.gov/pubmed/34206798 http://dx.doi.org/10.3390/ph14070613

Ejemplares similares

Impact of GSTA1 Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation
por: Michaud, Veronique, et al.
Publicado: (2019)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation
por: Hadjibabaie, M., et al.
Publicado: (2011)

Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation
por: Dadkhah, Adrin, et al.
Publicado: (2022)

Busulfan‐containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study
por: Wang, Yu‐Hung, et al.
Publicado: (2021)

Phenytoin as seizure prophylaxis in hematopoietic stem cell transplantation with busulfan conditioning
por: Germeraad, R. S., et al.
Publicado: (2022)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Prospective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation
por: Cho, Sang-Heon, et al.
Publicado: (2016)

Successful hematopoietic stem cell transplantation with reduced dose of busulfan for Omenn syndrome
por: Matsukawa, Yukihiro, et al.
Publicado: (2022)

Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan
por: Seydoux, Claire, et al.
Publicado: (2023)

Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation
por: Seydoux, Claire, et al.
Publicado: (2022)

GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study
por: Ansari, Marc, et al.
Publicado: (2017)

Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients
por: Akiyama, Kana, et al.
Publicado: (2018)

Combining Mobilizing Agents with Busulfan to Reduce Chemotherapy-Based Conditioning for Hematopoietic Stem Cell Transplantation
por: Garcia-Perez, Laura, et al.
Publicado: (2021)

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study
por: Liu, Hui, et al.
Publicado: (2013)

Is there any difference between busulfan-cyclophosphamide and cyclophosphamide-busulfan in patients underwent allogeneic transplantation?
por: Bahçecioğlu, Ömer Faruk, et al.
Publicado: (2021)

Can First-Dose Therapeutic Drug Monitoring Predict the Steady State Area Under the Blood Concentration-Time Curve of Busulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation?
por: Alsultan, Abdullah, et al.
Publicado: (2022)

Saliva as a noninvasive sampling matrix for therapeutic drug monitoring of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation: A prospective population pharmacokinetic and simulation study
por: Xu, Baohua, et al.
Publicado: (2023)

Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
por: Lee, Seung-Shin, et al.
Publicado: (2020)

External Evaluation of Population Pharmacokinetic Models of Busulfan in Chinese Adult Hematopoietic Stem Cell Transplantation Recipients
por: Huang, Huiping, et al.
Publicado: (2022)

Antitumor Activity and Neutrophil‐selective Hematopoietic Toxicity of Busulfan Analogs in Mice
por: Kato, Taketoshi, et al.
Publicado: (1988)

Implementation and Cross-Validation of a Pharmacokinetic Model for Precision Dosing of Busulfan in Hematopoietic Stem Cell Transplanted Children
por: Goutelle, Sylvain, et al.
Publicado: (2022)

Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission
por: Bueno, Nadjanara Dorna, et al.
Publicado: (2011)

Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients
por: Ansari, M, et al.
Publicado: (2016)

Busulfan and cyclosphamide induce liver inflammation through NLRP3 activation in mice after hematopoietic stem cell transplantation
por: Qiao, Jianlin, et al.
Publicado: (2015)

Busulfan systemic exposure and its relationship with efficacy and safety in hematopoietic stem cell transplantation in children: a meta-analysis
por: Feng, Xinying, et al.
Publicado: (2020)

Use of Busulfan to Condition Mice for Bone Marrow Transplantation
por: Montecino-Rodriguez, Encarnacion, et al.
Publicado: (2020)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation
por: Mehdizadeh, Mahshid, et al.
Publicado: (2021)

Safety and efficacy of a modified busulfan/cyclophosphamide conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation in acute myeloid leukemia
por: Shi, Yuan-Yuan, et al.
Publicado: (2023)

Association between busulfan exposure and survival in patients undergoing a CD34(+) selected stem cell transplantation
por: Tamari, Roni, et al.
Publicado: (2023)

Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation
por: Huezo-Diaz Curtis, P, et al.
Publicado: (2018)

Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan‐Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation
por: El‐Serafi, Ibrahim, et al.
Publicado: (2019)

Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study
por: Ben Hassine, Khalil, et al.
Publicado: (2021)

Effect of GSTA1 Variants on Busulfan-Based Conditioning Regimen Prior to Allogenic Hematopoietic Stem-Cell Transplantation in Pediatric Asians
por: Nguyen, Ai-Hoc, et al.
Publicado: (2022)

Hematopoietic stem cell transplantation for severe aplastic anemia—experience of an institute in Taiwan
por: Bai, L. Y., et al.
Publicado: (2003)

What is the minimum adequate busulfan dose for patients with sickle cell disease undergoing reduced intensity conditioning with fludarabine, busulfan, and anti‐thymocyte globulin?
por: AlJohani, Naif I., et al.
Publicado: (2021)

Comparison of Two Analytical Methods for Busulfan Therapeutic Drug Monitoring
por: De Gregori, Simona, et al.
Publicado: (2020)

Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation: can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia?
por: Lemoli, Roberto M., et al.
Publicado: (2011)

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia
por: Pidala, Joseph, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_e58b716bu93s2eg3veq4huckuq